GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » RVL Pharmaceuticals PLC (OTCPK:RVLPQ) » Definitions » Scaled Net Operating Assets

RVL Pharmaceuticals (RVL Pharmaceuticals) Scaled Net Operating Assets : 0.50 (As of Jun. 2023)


View and export this data going back to 2018. Start your Free Trial

What is RVL Pharmaceuticals Scaled Net Operating Assets?

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

RVL Pharmaceuticals's operating assets for the quarter that ended in Jun. 2023 was $66.25 Mil. RVL Pharmaceuticals's operating liabilities for the quarter that ended in Jun. 2023 was $10.93 Mil. RVL Pharmaceuticals's Total Assets for the quarter that ended in Mar. 2023 was $111.11 Mil. Therefore, RVL Pharmaceuticals's scaled net operating assets (SNOA) for the quarter that ended in Jun. 2023 was 0.50.


RVL Pharmaceuticals Scaled Net Operating Assets Historical Data

The historical data trend for RVL Pharmaceuticals's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

RVL Pharmaceuticals Scaled Net Operating Assets Chart

RVL Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Scaled Net Operating Assets
Get a 7-Day Free Trial 0.63 0.37 0.44 0.22 0.44

RVL Pharmaceuticals Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Scaled Net Operating Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.52 0.52 0.41 0.51 0.50

Competitive Comparison of RVL Pharmaceuticals's Scaled Net Operating Assets

For the Biotechnology subindustry, RVL Pharmaceuticals's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


RVL Pharmaceuticals's Scaled Net Operating Assets Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, RVL Pharmaceuticals's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where RVL Pharmaceuticals's Scaled Net Operating Assets falls into.



RVL Pharmaceuticals Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

RVL Pharmaceuticals's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Dec. 2022 is calculated as

Scaled Net Operating Assets (SNOA)(A: Dec. 2022 )
=(Operating Assets (A: Dec. 2022 )-Operating Liabilities (A: Dec. 2022 ))/Total Assets (A: Dec. 2021 )
=(83.967-19.928)/144.67
=0.44

where

Operating Assets(A: Dec. 2022 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=128.51 - 44.543
=83.967

Operating Liabilities(A: Dec. 2022 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=77.417 - 55.612 - 1.877
=19.928

RVL Pharmaceuticals's Scaled Net Operating Assets (SNOA) for the quarter that ended in Jun. 2023 is calculated as

Scaled Net Operating Assets (SNOA)(Q: Jun. 2023 )
=(Operating Assets (Q: Jun. 2023 )-Operating Liabilities (Q: Jun. 2023 ))/Total Assets (Q: Mar. 2023 )
=(66.245-10.931)/111.108
=0.50

where

Operating Assets(Q: Jun. 2023 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=85.404 - 19.159
=66.245

Operating Liabilities(Q: Jun. 2023 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=69.078 - 0.192 - 57.955
=10.931

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


RVL Pharmaceuticals Scaled Net Operating Assets Related Terms

Thank you for viewing the detailed overview of RVL Pharmaceuticals's Scaled Net Operating Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


RVL Pharmaceuticals (RVL Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
400 Crossing Boulevard, Bridgewater, NJ, USA, 08807
RVL Pharmaceuticals PLC is a pharmaceutical company focused on the commercialization and development of products that target markets with underserved patient populations in the ocular medicine and medical aesthetics therapeutic areas. Its revenues consist of product sales, royalty revenues and licensing revenue.
Executives
Foundation Harsaul 10 percent owner EDIFICIO AFRA, AVENIDA SAMUEL LEWIS Y CALLE 54, PANAMA R1
Altchem Ltd 10 percent owner KARAISKAKI 6, CITY HOUSE, LIMASSOL G4 3032
Alisa Lask director C/O 380 LACKAWANNA PLACE, SOUTH ORANGE NJ 07079
David F Burgstahler director, 10 percent owner C/O WARNER CHILCOTT HOLDINGS CO., LTD., 100 ENTERPRISE DRIVE, ROCKAWAY NJ 07866
Athyrium Opportunities Associates Iv Co-invest Llc 10 percent owner 505 FIFTH AVENUE, FLOOR 18, NEW YORK NY 10017
Athyrium Opportunities Associates Iv Lp 10 percent owner 505 FIFTH AVENUE, FLOOR 18, NEW YORK NY 10017
Athyrium Opportunities Associates Iv Gp Llc 10 percent owner 505 FIFTH AVENUE, FLOOR 18, NEW YORK NY 10017
Athyrium Opportunities Iv Co-invest 2 Lp 10 percent owner 505 FIFTH AVENUE, FLOOR 18, NEW YORK NY 10017
Athyrium Opportunities Iv Acquisition 2 Lp 10 percent owner 505 FIFTH AVENUE, FLOOR 18, NEW YORK NY 10017
Athyrium Funds Gp Holdings Llc 10 percent owner 505 FIFTH AVENUE, FLOOR 18, NEW YORK NY 10017
Avista Healthcare Partners, L.p. 10 percent owner 65 E. 55TH STREET, 18TH FLOOR, NEW YORK NY 10022
Brian A Markison director, officer: Chief Executive Officer 501 FIFTH STREET, BRISTOL TN 37620
Sriram Venkataraman director, 10 percent owner C/O AVISTA CAPITAL PARTNERS, 65 EAST 55TH STREET, 18TH FLOOR, NEW YORK NY 10022
Jeffrey Ferrell 10 percent owner ATHYRIUM CAPITAL MANAGEMENT, LP, 505 FIFTH AVENUE, FL 18, NEW YORK NY 10017
James Schaub officer: EVP and COO 400 CROSSING BOULEVARD, C/O OSMOTICA PHARMACEUTICALS PLC, BRIDGEWATER NJ 08807